Article
Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
22 Aug 2017
Abstract excerpt
Poly-(ADP-ribose) polymerase (PARP) inhibitors act through synthetic lethality in cells with defects in homologous recombination (HR) DNA repair caused by molecular aberrations such as BRCA mutations, and is approved for treatment in ovarian cancer, with promising clinical activity against other HR defective tumors including breast and prostate cancers. Three PARP inhibitors have been FDA approved, while another...
Topics
Join the communities discussing this publication.